跳至主要内容
CAS 0 条记录

CAS 104987-11-3

CAS 104987-11-3 与法规 1223/2009 附件 II–VI 中的 0 条欧盟附件记录相匹配。

CAS 104987-11-3 的记录

0 共
未找到此 CAS 编号的记录。

化学身份与性质

CAS 104987-11-3 的 PubChem 二维化学结构
CAS 104987-11-3PubChem CID 445643

Tacrolimus

Tacrolimus is a calcineurin inhibitor and potent immunosuppressive agent used largely as a means of prophylaxis against cellular rejection after transplantation. Tacrolimus therapy can be associated with mild serum enzyme elevations, and it has been linked to rare instances of clinically apparent cholestatic liver injury. — LiverTox

IUPAC 名称
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
分子式
C44H69NO12
分子量
804.0 g/mol
精确质量
803.48197664 Da
XLogP3
2.7
拓扑极性表面积
178.0 Ų
氢键供体
3
氢键受体
12
共价单元
1
已定义的立体中心
14

又称

FujimycinPrografTsukubaenolideAdvagrafModigrafProtopicTacrolimus anhydrousFK506
另有 16 个已报告名称
FK 506ProtopyAnhydrous TacrolimusTACROLIMUS MONOHYDRATEEnvarsusAvagrafFR-900506PrograftTacrolimus, anhydrousAstagraf XLEnvarsus XRTacrolimus (anhydrous)AdoportCapexionHecoriaPerixis
外部数据库标识符

来自其他科学数据库的证据

EMBL-EBI ChEBI
标识符精确匹配CHEBI:61049

tacrolimus (anhydrous)

A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.

配方
C44H69NO12
平均质量
804.031 g/mol
单同位素质量
803.48198 Da
形式电荷
0
  • macrolide lactam — is a (CHEBI:145565)
  • bacterial metabolite — has role (CHEBI:76969)
  • immunosuppressive agent — has role (CHEBI:35705)
  • bacterial metabolite — has role (CHEBI:76969)
  • immunosuppressive agent — has role (CHEBI:35705)
  • macrolide lactam — is a (CHEBI:145565)
其他整理的名称
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadec8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN(-)-FK 506FK 506FK506tacrolimusTacrolimustacrolimus anhydrous
来自此来源的交叉引用
  • CAS: 104987-11-3 — KEGG COMPOUND
  • CAS: 104987-11-3 — ChemIDplus
  • CAS: 104987-11-3 — KEGG DRUG
  • REGISTRY_NUMBER: 3647477 — Reaxys
  • REGISTRY_NUMBER: 8821611 — Reaxys
  • MANUAL_X_REF: C01375 — KEGG COMPOUND
  • MANUAL_X_REF: D08556 — KEGG DRUG
  • MANUAL_X_REF: DB00864 — DrugBank
  • MANUAL_X_REF: EP184162 — Patent
  • MANUAL_X_REF: FK5 — PDBeChem
  • MANUAL_X_REF: LMPK04000003 — LIPID MAPS
  • MANUAL_X_REF: US5665727 — Patent

映射方: Exact CAS cross-reference in the ChEBI compound record. 来源更新: 2019-12-03. 检索时间: 2026-08-31. 打开来源记录

NIH PubChem PUG-View
标识符精确匹配445643

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17Њ±10%; in adults liver transplant patients is 22Њ±6%; in healthy subjects is 18Њ±5%. The absolute bioavailability in pediatric liver transplant patients was 31Њ±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition. 来源: Toxin and Toxin Target Database (T3DB)
  • Signal: Danger 来源: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (97.6%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (92.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (91.5%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] 来源: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P301+P316, P318, P319, P321, P330, P405, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 82 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (100%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] 来源: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 来源: European Chemicals Agency (ECHA)
  • Signal: Danger 来源: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H301: Toxic if swallowed [Danger Acute toxicity, oral] 来源: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) 来源: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: IDENTIFICATION AND USE: Tacrolimus is white to off-white crystalline powder. It is a calcineurin-inhibitor immunosuppressant available in several preparations. Tacrolimus in both oral capsules and a solution for IV injection is used for prophylaxis of organ rejection in patients receiving liver, kidney or heart transplants. Tacrolimus topical ointment is used as a second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children. HUMAN EXPOSURE AND TOXICITY: While most acute overdosages of tacrolimus at up to 30 times the intended dose have been asymptomatic and all patients recovered with no sequelae, some acute overdosages were followed by adverse reactions including tremors, abnormal renal function, hypertension, and peripheral edema. At therapeutic doses, patients receiving tacrolimus are at increased risk of developing lymphomas and other malignancies, particularly of the skin, as well as an increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. While there a 来源: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: Signs and Symptoms of Overdose; Tacrolimus toxicity commonly presents as acute kidney injury. Close monitoring of serum creatinine, glomerular filtration rate, and urine output is necessary for patients on tacrolimus. Toxicity may also present as adverse effects, including tremors, electrolyte disturbances, and headaches. Monitor for neurotoxicity, nephrotoxicity, and hypertension. Investigations may indicate increased serum creatinine. An electrocardiogram should be obtained to rule out QT prolongation.; Management of Overdose; No specific antidote is currently available for tacrolimus toxicity, and the drug is not removed by hemodialysis. Management focuses on supportive care, including symptom monitoring and management. Consultation with the poison control center is recommended for current guidance and treatment recommendations. 来源: StatPearls
  • Toxicity Summary: The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells. 来源: Toxin and Toxin Target Database (T3DB)
  • Uses: THERAPEUTIC CATEGORY: Immunosupressant; dermatological treatment of atopic eczema 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Immunosuppressive Agents 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg; approx.) in Germany (2009): >25; Use (kg) in USA (2002): 45; Consumption (g per capita; approx.) in Germany (2009): 0.000305; Consumption (g per capita) in the USA (2002): 0.00016; Calculated removal (%): 6 来源: NORMAN Suspect List Exchange
  • Uses: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis. 来源: Toxin and Toxin Target Database (T3DB)

映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录

科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。

其他来源的覆盖范围和匹配状态
来源结果已检查
EMBL-EBI ChEBI精确匹配2026-08-31
NIH PubChem PUG-View精确匹配2026-08-31

已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。

于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

本站如何使用 CAS 104987-11-3

CAS 104987-11-3 是化学文摘社 (Chemical Abstracts Service) 的标识符,用于将本页对应到特定物质。在当前数据集中,有 0 条欧盟附件记录共用该标识符,可帮助您交叉核对同一物质是出现在一种还是多种监管情境中。

当供应商规格书、SDS 或原料档案给出 CAS 104987-11-3,而您需要在一处查看所有关联的附件 II–VI 记录时,请使用本页。上方的条目卡片是查看浓度限值、警示语、附件归属和产品类型条件的最快途径。